Tien Liang BioTech Co., Ltd.
Tien Liang BioTech Co., Ltd. manufactures and sells pharmaceutical products in Taiwan. The company offers Chinese medicine products, such as pills for liver and kidney deficiency, lower back pain and sore feet, dizziness and blurred vision, thirst, dry tongue and sore throat, and heel pain, as well as rheumatic pain, joint pain, generalized pain, wind-cold-dampness arthralgia, gout, neuralgia, be… Read more
Tien Liang BioTech Co., Ltd. (4127) - Total Assets
Latest total assets as of September 2025: NT$1.22 Billion TWD
Based on the latest financial reports, Tien Liang BioTech Co., Ltd. (4127) holds total assets worth NT$1.22 Billion TWD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Tien Liang BioTech Co., Ltd. - Total Assets Trend (2020–2024)
This chart illustrates how Tien Liang BioTech Co., Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Tien Liang BioTech Co., Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
Tien Liang BioTech Co., Ltd.'s total assets of NT$1.22 Billion consist of 27.7% current assets and 72.3% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 14.7% |
| Accounts Receivable | NT$42.05 Million | 4.7% |
| Inventory | NT$58.49 Million | 6.6% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Tien Liang BioTech Co., Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tien Liang BioTech Co., Ltd.'s current assets represent 27.7% of total assets in 2024, a decrease from 40.3% in 2020.
- Cash Position: Cash and equivalents constituted 14.7% of total assets in 2024, down from 18.4% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is inventory at 6.6% of total assets.
Tien Liang BioTech Co., Ltd. Competitors by Total Assets
Key competitors of Tien Liang BioTech Co., Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Tien Liang BioTech Co., Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Tien Liang BioTech Co., Ltd. generates 0.43x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Tien Liang BioTech Co., Ltd. generates $ 1.32 in net profit.
Tien Liang BioTech Co., Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.47 | 1.60 | 1.90 |
| Quick Ratio | 0.39 | 1.38 | 1.27 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$-394.90 Million | NT$ 167.45 Million | NT$ 146.83 Million |
Tien Liang BioTech Co., Ltd. - Advanced Valuation Insights
This section examines the relationship between Tien Liang BioTech Co., Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.54 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | 35.9% |
| Total Assets | NT$888.68 Million |
| Market Capitalization | $22.32 Million USD |
Valuation Analysis
Below Book Valuation: The market values Tien Liang BioTech Co., Ltd.'s assets below their book value (0.03 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Tien Liang BioTech Co., Ltd.'s assets grew by 35.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Tien Liang BioTech Co., Ltd. (2020–2024)
The table below shows the annual total assets of Tien Liang BioTech Co., Ltd. from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$888.68 Million | +35.88% |
| 2023-12-31 | NT$654.03 Million | -3.31% |
| 2022-12-31 | NT$676.43 Million | +3.22% |
| 2021-12-31 | NT$655.35 Million | +4.87% |
| 2020-12-31 | NT$624.94 Million | -- |